Skip to main content

Table 3 Multiple logistic regression analysis for HCV treatment effect on aggressiveness index score

From: Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy

Parameter1

 

Adj. Odds

S.E OR

95% CI

P-value2

Sex

Female

Reference

0.400

Male

0.707

0.412

0.315 to 1.585

 

Age (yr)

>  55

Reference

0.055

≤ 55

2.064

0.397

0.983 to 4.336

 

DM

No

Reference

0.219

Yes

1.650

0.407

0.743 to 3.663

 

Tobacco

No

Reference

0.194

Yes

0.596

0.399

0.272 to 1.303

Plt (× 109/L)

≤ 150

Reference

0.109

<  150

2.023

0.451

0.836 to 4.894

NLR

≤ 2.5

Reference

0.429

>  2.5

1.408

0.435

0.600 to 3.304

AgI

Score = 4

Reference

0.021

Score 5–8

2.469

0.801

0.514 to 11.857

Score > 8

6.919

0.873

1.249 to 38.332

  1. 1Overall Model was applied while considering HCV treatment naïve patients as reference 2 P-value < 0.05 was considered as significant
  2. HCV Hepatitis-C Virus; HCC Hepatocellular carcinoma; DM Diabetes Mellitus; Plt Platelet count; NLR Neutrophil to lymphocyte ratio; AgI Aggressiveness Index (sum of score) = Maximum Tumor Diameter (MTD) (in tertiles): MTD < 4.5; 4.5 = MTD = 9.6; MTD > 9.6; scores 1, 2, 3 respectively; Alpha-fetoprotein (AFP) (cut-off): AFP < 100; 100 = AFP = 1000; AFP > 1000; scores 1, 2, 3 respectively; Portal Vein Thrombosis (PVT) (no/yes): PVT (no); PVT (yes); scores 1, 3 respectively; nodules (number): Nodules = 3; nodules > 3; scores 1, 3 respectively